Related Experiment Video

Updated: Apr 6, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia

Sandrine Degryse1,2, Jan Cools3,4,5

  • 1VIB Center for the Biology of the Disease, Leuven, Belgium. sandrine.degryse@cme.vib-kuleuven.be.

Journal of Hematology & Oncology
|July 26, 2015
PubMed

Insights

Activating mutations in the interleukin-7 receptor complex (IL7R) are found in acute lymphoblastic leukemia. Investigating JAK1 and JAK3 kinase inhibitors may offer targeted treatments for these leukemias.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy.
  • Recent research implicates the interleukin-7 receptor (IL7R) complex in ALL pathogenesis.
  • Activating mutations have been identified in IL7R, JAK1, and JAK3 components.

Purpose of the Study:

  • To explore the therapeutic potential of targeting the IL7R signaling pathway in ALL.
  • To investigate the efficacy of JAK1 and JAK3 kinase inhibitors as targeted agents for ALL.

Main Methods:

  • Genomic analysis of ALL patient samples to identify mutations in IL7R pathway components.
  • In vitro kinase assays to assess the activity of JAK1 and JAK3.
  • Preclinical studies evaluating the effects of JAK1 and JAK3 inhibitors on ALL cell lines and patient-derived xenografts.

Main Results:

  • Confirmation of activating mutations in IL7R, JAK1, and/or JAK3 in a subset of ALL cases.
  • Demonstration of aberrant signaling through the IL7R pathway in mutated cells.
  • Significant anti-leukemic activity observed with JAK1 and JAK3 kinase inhibitors in preclinical models.

Conclusions:

  • The IL7R signaling pathway is a relevant target in acute lymphoblastic leukemia.
  • JAK1 and JAK3 kinase inhibitors represent promising targeted therapies for ALL patients with specific mutations.
  • Further clinical investigation of these inhibitors in ALL is warranted.

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

922

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
652
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.0K